Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05403476 · ClinicalTrials.gov registry record · Phase 2
A Trial to Compare Efficacy and Safety of Follitropin Delta Versus Placebo (Inactive Treatment) in the Treatment of Men With Idiopathic Infertility (Unexplained Reduction of Semen Quality) (ADAM)
A Phase 2 study, sponsored by Ferring Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT05403476 is a Phase 2 study that was terminated before completion, run by Ferring Pharmaceuticals. The registered enrollment target is 4 participants.
The verdict
NCT05403476, a Phase 2 study, was terminated before completion, sponsored by Ferring Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
The primary purpose of this trial is to investigate whether men with idiopathic infertility (unexplained reduction of semen quality), after being treated with a daily dose of 12 µg recombinant follicle stimulating hormone (rFSH) for 6 months, can improve the chance of spontaneous pregnancy observed in their female partners in comparison to placebo (inactive treatment). For more information, please visit the trial's website www.adamclinicaltrial.com (only applicable in the US).
Interventions
- DRUG Placebo
- DRUG FE 999049
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2022-08-16 |
| Est. Completion | 2024-10-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05403476
The ClinicalTrials.gov registry entry for NCT05403476 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ferring Pharmaceuticals, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05403476 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05403476 about?
NCT05403476 is a clinical study titled "A Trial to Compare Efficacy and Safety of Follitropin Delta Versus Placebo (Inactive Treatment) in the Treatment of Men With Idiopathic Infertility (Unexplained Reduction of Semen Quality) (ADAM)". The primary purpose of this trial is to investigate whether men with idiopathic infertility (unexplained reduction of semen quality), after being treated with a daily dose of 12 µg recombinant follicle stimulating hormone (rFSH) for 6 months, can improve the chance of spontaneous pregnancy observed ...
What is the current status of trial NCT05403476?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2022-08-16. Estimated completion is 2024-10-23.
What interventions are being tested in trial NCT05403476?
The interventions under investigation include: Placebo (DRUG), FE 999049 (DRUG).
Who is sponsoring clinical trial NCT05403476?
This trial is sponsored by Ferring Pharmaceuticals, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.